Tumor discovery最新文献_第3页

Benefits and harms of screening: Overdiagnosis and anticipatory medicine – A secondary publication 筛查的利弊:过度诊断和预见性医学-二次出版

Tumor discovery Pub Date : 2022-11-17 DOI: 10.36922/td.v1i2.228

A. Zarazaga Monzón, Á. Franco-López, J. Culebras

{"title":"Benefits and harms of screening: Overdiagnosis and anticipatory medicine – A secondary publication","authors":"A. Zarazaga Monzón, Á. Franco-López, J. Culebras","doi":"10.36922/td.v1i2.228","DOIUrl":"https://doi.org/10.36922/td.v1i2.228","url":null,"abstract":"The treatment of breast cancer has changed markedly since the publication of works that recommend screening for the early diagnosis of breast cancer. Retrospective reevaluations have revealed errors in screening; moreover, advances in oncological therapy and a better understanding of the disease have raised doubts toward the efficacy of these procedures, which might also cause side effects alongside the risk of overdiagnosis and overtreatment. On the other hand, the lack of information or even misinformation might cause confusion among the potential beneficiaries of these procedures, particularly the patients. These procedures are constantly being recommended by institutions, but the possible risks accompanied by these procedures are often not explained. It is easy to promote mammography screening if the majority believe that it reduces the risk of breast cancer and saves lives. Unfortunately, this is not the case. Many critics of screening are now demanding clear and precise explanations of the procedure and emphasizing on the importance of physical examination. Women must make informed decisions before screening by discussing their own risk profile, the possible benefits, and the eventual risks and harms of mammogram with their physicians. Women should be classified into two groups: those who would gain potential benefits from the procedure and those whose risks outweigh the benefits. A screening program that clearly does not offer more benefits than risks cannot be implemented by public heath institutions. Providing complete and unbiased information, promoting appropriate care, as well as preventing overdiagnosis and overtreatment would be the best option.","PeriodicalId":94260,"journal":{"name":"Tumor discovery","volume":"77 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90627111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

A N6-methyladenosine-related long noncoding RNA is a potential biomarker for predicting pancreatic cancer prognosis n6 -甲基腺苷相关长链非编码RNA是预测胰腺癌预后的潜在生物标志物

Tumor discovery Pub Date : 2022-10-11 DOI: 10.36922/td.v1i2.165

Yiyang Chen, Wanbang Zhou, Yiju Gong, Xi Ou

{"title":"A N6-methyladenosine-related long noncoding RNA is a potential biomarker for predicting pancreatic cancer prognosis","authors":"Yiyang Chen, Wanbang Zhou, Yiju Gong, Xi Ou","doi":"10.36922/td.v1i2.165","DOIUrl":"https://doi.org/10.36922/td.v1i2.165","url":null,"abstract":"Pancreatic cancer is a common malignant tumor of the digestive system, with insidious onset, difficult early diagnosis, easy metastasis, and poor prognosis. N6-methyladenosine (m6A) and long non-coding RNA (lncRNA) play important roles in the prognostic value and immunotherapy response of pancreatic adenocarcinoma (PAAD). Therefore, it is crucial to recognize m6A-related-lncRNAs in PAAD patients. In this study, m6A-related lncRNAs were obtained by coexpression analysis. Univariate, the Least Absolute Shrinkage, and Selection Operator (LASSO) and multivariate Cox regression analyses were performed to construct m6A-related lncRNA prognostic models. Kaplan–Meier analysis, principal component analysis, feature-rich annotation, and nomogram were used to analyze the accuracy of risk models. Potential drugs targeting this model are also discussed. A prognostic model based on m6A-related lncRNAs was constructed, potential drugs targeting this m6A-related lncRNAs feature were discovered, and the relationship with immunotherapy response was studied. Finally, a nomogram was established to predict survival in PAAD patients. This m6A-based lncRNAs risk prognostic model may be promising for clinical prediction of prognosis and immunotherapy response in PAAD patients.","PeriodicalId":94260,"journal":{"name":"Tumor discovery","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80856349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Cystic hygroma in a young adult: A case report and recent management 青年人囊性水肿1例报告及近期处理

Tumor discovery Pub Date : 2022-08-30 DOI: 10.36922/td.v1i2.151

S. Kadam, Tejaswini Kadam

引用次数: 0

Editor’s foreword to the inaugural issue of Tumor Discovery 《肿瘤发现》创刊号的编者前言

Tumor discovery Pub Date : 2022-05-11 DOI: 10.36922/td.v1i1.86

Mingzhu Yin

引用次数: 0

Combined anti-PD1 immunotherapy for patient with advanced pancreatic cancer: A case report 联合抗pd1免疫治疗晚期胰腺癌1例报告

Tumor discovery Pub Date : 2022-05-06 DOI: 10.36922/td.v1i1.52

Zhe Jiang, Hongyan Li, Fei Li

引用次数: 1

Dual-targeting and specific delivery of tamoxifen to cancer cells by modified magnetic nanoparticles using hyaluronic acid and folic acid 利用透明质酸和叶酸修饰的磁性纳米颗粒对癌细胞的双靶向和特异性递送他莫昔芬

Tumor discovery Pub Date : 2022-04-28 DOI: 10.36922/td.v1i1.41

Mostafa Heidari Majd

{"title":"Dual-targeting and specific delivery of tamoxifen to cancer cells by modified magnetic nanoparticles using hyaluronic acid and folic acid","authors":"Mostafa Heidari Majd","doi":"10.36922/td.v1i1.41","DOIUrl":"https://doi.org/10.36922/td.v1i1.41","url":null,"abstract":"Tamoxifen (TMX) which serves as the best clinical option for the treatment of breast cancer may trigger major dose-dependent side effects due to its poor solubility. Therefore, the use of lower TMX doses utilizing nano-enabled drug delivery systems offers multiple benefits to improving drug specified concentration, safety, and long-term release. In this study, we synthesized targeted magnetic nanoparticles (MNPs) containing folic acid (FA) and hyaluronic acid (HA) to improve drug delivery of TMX. After investigations utilizing Fourier-transform infrared spectroscopy and field emission scanning electron microscope, we found that the surface of MNPs was well modified with targeting agents, and the size of the Fe3O4-DPN-HA-FA NPs was determined at ∼153 (±3.3) nm. Furthermore, the release of 81% TMX after 120 h indicated that there was a controlled pattern of drug release from the modified MNPs. Besides that, the MTT assay revealed that the viability of MDA-MB-231 cell lines after 48 h and 72 h of treatment is dependent on the time and concentration of Fe3O4-DPN-HA-FA-TMX NPs. Finally, real-time polymerase chain reaction demonstrated that Fe3O4-DPN-HA-FA-TMX NPs could upregulate the expression of Bak1 genes and downregulated the expression of Bclx genes during 24 h treatment. All data confirmed that the presence of HA and FA on the surface of nanocarriers and the active targeting employing the nanocarriers can be a useful step to obliterate the breast cancer cells.","PeriodicalId":94260,"journal":{"name":"Tumor discovery","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86914785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The clinicopathological and prognostic significance of PD-1 expression in cancers: A bioinformatics analysis 肿瘤中PD-1表达的临床病理和预后意义:生物信息学分析

Tumor discovery Pub Date : 2022-04-15 DOI: 10.36922/td.v1i1.59

Shuai Shi, Zhi-Gang Zhang, Guangtao Ma, Hongyan Ma

{"title":"The clinicopathological and prognostic significance of PD-1 expression in cancers: A bioinformatics analysis","authors":"Shuai Shi, Zhi-Gang Zhang, Guangtao Ma, Hongyan Ma","doi":"10.36922/td.v1i1.59","DOIUrl":"https://doi.org/10.36922/td.v1i1.59","url":null,"abstract":"Background: Programmed cell death protein 1 (PD-1), which is encoded by PDCD1 gene, is a cell-surface protein of immunoglobin family. A number of published studies have reported the relationship between PD-1 expression and prognosis in cancers. The purpose of our study was to identify an independent prognostic marker. \u0000Methods: In the present study, we investigated the prognostic value of PD-1 mRNA expression through the Kaplan–Meier plotter databases. \u0000Results: The expression of PD-1 mRNA was negatively related with the overall survival (OS) rate of gastric cancer, but positively associated with the OS rate of breast cancer, ovarian cancer and liver cancer (P < 0.05). High PD-1 mRNA expression was linked to an improved relapse-free survival rate of breast cancer, ovarian cancer, and liver cancer (P < 0.05). There was a negative correlation with post-progression survival in gastric cancer (P < 0.05). Besides, there was a positive correlation with progression-free survival and disease specific survival in liver cancer. We also further evaluated the prognostic value of PD-1 in relation to different clinicopathological features of cancers. \u0000Conclusion: Our results showed that PD-1 expression might be a good marker for the prognosis of patients with cancers, which highlights new methods and ideas for preventive treatment.","PeriodicalId":94260,"journal":{"name":"Tumor discovery","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83741838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Advances in the study of the pathogenesis of cancer-related cognitive impairment 癌症相关认知障碍发病机制的研究进展

Tumor discovery Pub Date : 2022-03-22 DOI: 10.36922/td.v1i1.46

Jiwei Jiang, Z. Du, Yanli Wang, H. Shi, Wenyi Li, Yuan Zhang, Mengfan Sun, Zhimin Bian, Jun Xu

{"title":"Advances in the study of the pathogenesis of cancer-related cognitive impairment","authors":"Jiwei Jiang, Z. Du, Yanli Wang, H. Shi, Wenyi Li, Yuan Zhang, Mengfan Sun, Zhimin Bian, Jun Xu","doi":"10.36922/td.v1i1.46","DOIUrl":"https://doi.org/10.36922/td.v1i1.46","url":null,"abstract":"Advances in diagnostic and therapeutic strategies have significantly contributed to an increase in the survival rate of cancer patients. Recently, several studies suggested that cancer patients may exhibit symptoms of cognitive impairment before, during and even many years after the completion of therapies, negatively impacting the quality of life and functional independence of cancer survivors. Clinically, the coexistence of cancer and cognitive impairment reminds scientists of paraneoplastic syndrome, especially limbic encephalitis. However, some cancer patients show symptoms of cognition deterioration after treatment, without any typical psychiatric symptoms, epileptic seizures or positive antineuronal antibodies, suggesting that the relationship between cancer and cognitive deficits is more common than previously anticipated. Most importantly, many aspects of the association between cancer and cognitive impairment remain uncertain. The definitive connection between systemic cancer and central nervous system is yet to be established. Therefore, this review summarizes the current evidence on the potential pathophysiology in these patients with cancer-related cognitive impairment, and reviews the knowledge gaps and the potential counteracting strategies.","PeriodicalId":94260,"journal":{"name":"Tumor discovery","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85405629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monocytes in tumor: from the sight of Single-cell analysis 肿瘤中的单核细胞:从单细胞的角度分析

Tumor discovery Pub Date : 2022-03-10 DOI: 10.36922/td.v1i1.4

Xin Fu, Mingzhu Yin

引用次数: 1

Receptors of advanced glycation end products in oral squamous cell carcinoma: A systematic review 口腔鳞状细胞癌晚期糖基化终产物受体:系统综述

Tumor discovery Pub Date : 2020-08-23 DOI: 10.36922/td.244

Sinduja Palati, P. Ramani, H. Sherlin, S. Gheena, A. Ramasubramanian, K. Don, G. Jayaraj, Archana Santhanam

引用次数: 1